Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in
combination with external beam radiotherapy (EBRT) vs. external beam radiotherapy alone in
the treatment of advanced castration resistant prostate carcinoma with limited bone
metastases.
To evaluate if time to radiological progression according to the "Recommendations of the
Prostate Cancer Clinical Trials Working Group" published by Scher et al. (JCO 2008) (based on
new lesions in bone scan and CT /MRI or death) of Radium-223 dichloride combined with EBRT is
superior compared to EBRT alone.